drugset / Trial / NCT00556439

Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

NCT00556439

RandomizedParallel-groupDouble-blindTreatment

Summary

Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are diseases that cause swelling of the arteries in the head, neck, upper body, and arms. TAK specifically affects the aorta, the largest blood vessel in the body, and its branches. Therapies are available to improve the symptoms of GCA and TAK, but relapse often occurs, and better treatments are needed. Abatacept is a drug that interacts with certain cells in the body that are involved with GCA and TAK. This study will evaluate the effectiveness of abatacept in treating GCA and TAK and preventing disease relapse.

Timeline

Start
2008-12
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 500 mg Intravenous
Subject Abatacept Other / unclassified 750 mg Intravenous
Subject Abatacept Other / unclassified 1000 mg Intravenous